AI and genetics are creating a 'seismic shift' in the pharmaceutical business, experts on Asian Financial Forum panel say ...
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncologic, ...
Qilu Pharmaceutical has struck a deal to tap into Insilico Medicine’s artificial intellige | Qilu Pharmaceutical has struck a ...
The AHA Jan. 26 urged the Health Resources and Services Administration to take immediate action to stop a new Eli Lilly and ...
The American Hospital Association (AHA) expresses serious concerns with the recent announcement by Eli Lilly and Company (Lilly) to require 340B covered entities to submit claims data for all ...
What do you get when you insert a molecular glue degrader into an antibody-drug conjugate (ADC)? Fortitude Biomedicines is in ...
One llama is sprawled on the grass with its neck craned, basking in a patch of sunshine. Another stands on a dirt hill, ears ...
The market is poised for growth (12.88% CAGR), driven by high demand for equipment due to capacity expansions, and the adoption of single-use systems, continuous bioprocessing, and digital twinsDublin ...
It can take a decade and $2 billion to bring a new drug to market, pharmaceutical companies say. Many, including Eli Lilly, ...
From opening new therapeutic mechanisms to repairing neuronal damage, investigational molecules from Ventyx Therapeutics, AC ...
The RET fusion-targeted therapy market is set for strong expansion, driven by growing awareness of the oncogenic role of RET gene fusions and ...
Eli Lilly expand 340B reporting requirements to include all covered entities submitting claims-level data by Feb. 1, 2026, with some state exemptions.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results